<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>AstraZeneca plc - Oʻzgarishlar tarixi</title>
		<link>https://ziyosfera.uz/index.php?title=AstraZeneca_plc&amp;action=history</link>
		<description>Ziyosferadagi mazkur sahifaning oʻzgarishlar tarixi</description>
		<language>uz</language>
		<generator>MediaWiki 1.45.1</generator>
		<lastBuildDate>Fri, 20 Nov 2026 02:21:42 GMT</lastBuildDate>
		<item>
			<title>Programmer: Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.</title>
			<link>https://ziyosfera.uz/index.php?title=AstraZeneca_plc&amp;diff=299876&amp;oldid=prev</link>
			<guid isPermaLink="false">https://ziyosfera.uz/index.php?title=AstraZeneca_plc&amp;diff=299876&amp;oldid=prev</guid>
			<description>&lt;p&gt;Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Yangi sahifa&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Infobox company&lt;br /&gt;
| name = AstraZeneca plc&lt;br /&gt;
| logo = AstraZeneca.svg&lt;br /&gt;
| image = AstraZeneca HQ in Cambridge UK.jpg&lt;br /&gt;
| image_caption = The AstraZeneca Corporate HQ in [[Cambridge]], Angliya&lt;br /&gt;
| type = [[Ochiq maʼsuliyati cheklangan kompaniya]]&lt;br /&gt;
| traded_as = {{lse|AZN}}&amp;lt;br /&amp;gt;[[FTSE 100]] component&amp;lt;br /&amp;gt;{{nowrap|{{OMX|SSE3524|AZN}}}}&amp;lt;br /&amp;gt;[[OMX Stockholm 30]] component&amp;lt;br /&amp;gt;{{Nasdaq|AZN}} ([[American depository shares]])&amp;lt;br /&amp;gt;[[Nasdaq-100]] component&lt;br /&gt;
| ISIN = GB0009895292&lt;br /&gt;
| industry = [[Pharmaceutical industry|Farmatsevtika]]&amp;lt;br /&amp;gt;[[Biotexnologiya]]&lt;br /&gt;
| predecessors = {{ubl|[[Astra AB]]|[[Zeneca|Zeneca Group plc]]}}&lt;br /&gt;
| founded = {{start date and age|df=yes|1999|4|6}}&lt;br /&gt;
| location = [[Cambridge]], Angliya&lt;br /&gt;
| area_served = Global&lt;br /&gt;
| key_people = [[Leif Johansson (biznesmen)|Leif Johansson]]&amp;lt;br /&amp;gt;{{small|([[Rais]])}}&amp;lt;br /&amp;gt;[[Pascal Soriot|Sir Pascal Soriot]]&amp;lt;br /&amp;gt;{{small|([[CEO]])}}&lt;br /&gt;
| products = Farmatsevtika&lt;br /&gt;
| revenue = {{increase}} [[United States dollar|US$]]37.417&amp;amp;nbsp;mlrd (2021)&amp;lt;ref name=&amp;quot;results&amp;quot;&amp;gt;{{Cite web |title=Annual Results 2021 |url=https://www.astrazeneca.com/content/dam/az/PDF/2021/full-year/Full-year-2021-results-announcement.pdf |access-date=14 February 2022 |publisher=AstraZeneca}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
| operating_income = {{decrease}} US$1.056&amp;amp;nbsp;mlrd (2021)&amp;lt;ref name=results /&amp;gt;&lt;br /&gt;
| net_income = {{decrease}} US$0.115&amp;amp;nbsp;mlrd (2021)&amp;lt;ref name=results /&amp;gt;&lt;br /&gt;
| assets = {{increase}} US$105.363&amp;amp;nbsp;mlrd (2021)&amp;lt;ref name=results /&amp;gt;&lt;br /&gt;
| equity = {{increase}} US$39.287&amp;amp;nbsp;mlrd (2021)&amp;lt;ref name=results /&amp;gt;&lt;br /&gt;
| num_employees = 76,100 (2020)&amp;lt;ref name=results /&amp;gt;&lt;br /&gt;
| parent =&lt;br /&gt;
| divisions =&lt;br /&gt;
| subsid = [[Alexion Pharmaceuticals]]&amp;lt;br /&amp;gt;[[MedImmune]]&lt;br /&gt;
| website = {{URL|https://www.astrazeneca.com}}&lt;br /&gt;
}}&amp;#039;&amp;#039;&amp;#039;AstraZeneca plc&amp;#039;&amp;#039;&amp;#039; ({{IPAc-en|ˌ|æ|s|t|r|ə|ˈ|z|ɛ|n|ə|k|ə}}) — Britaniya-Shvetsiya ko‘p millatli farmatsevtika va [[biotexnologiya]] kompaniyasi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=AstraZeneca &amp;gt; GC Powerlist: Sweden Teams 2019|url=https://www.legal500.com/gc-powerlist/sweden-teams-19/astrazeneca-3/|kirish sanasi=2020-12-30|ish=www.legal500.com}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|muallif=Hollingsworth|ism=Julia|sana=2020-12-30|sarlavha=UK &amp;quot;will be able to get out of this by the spring&amp;quot;, minister says after regulator approves AstraZeneca vaccine|url=https://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-30-20/h_34768b64123b61496556589aa542388f|kirish sanasi=2020-12-30|ish=CNN|til=en}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|muallif=biopharma-reporter.com|sarlavha=AstraZeneca&amp;#039;s COVID-19 vaccine gets the green light in the UK|url=https://www.biopharma-reporter.com/Article/2020/12/30/AstraZeneca-COVID-19-vaccine-authorized-in-UK|kirish sanasi=2020-12-30|ish=biopharma-reporter.com|til=en-GB|qaralgan sana=2022-12-07|arxivsana=2021-01-09|arxivurl=https://web.archive.org/web/20210109205941/https://www.biopharma-reporter.com/Article/2020/12/30/AstraZeneca-COVID-19-vaccine-authorized-in-UK}}&amp;lt;/ref&amp;gt; shtab-kvartirasi Angliya Kembrijdagi [[Cambridge|Kembrij]] biotibbiyot kampusida joylashgan&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Registered office and corporate headquarters|url=https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html|kirish sanasi=27 February 2020|nashriyot=AstraZeneca}}&amp;lt;/ref&amp;gt;. U [[onkologiya]], yurak- qon tomir, oshqozon-[[Gastroenterologiya|ichak]], [[infeksiya]], nevrologiya, [[Pulmonologiya|nafas olish]] va [[yalligʻlanish]] kabi sohalardagi asosiy kasalliklar uchun mahsulotlar portfeliga ega. U [[Oxford–AstraZeneca COVID-19 vaksinasi|Oksford-AstraZeneca COVID-19 vaksinasini yaratishda]] ishtirok etgan&amp;lt;ref&amp;gt;{{Veb manbasi|sana=2020-09-18|sarlavha=A history of AstraZeneca|url=https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/|kirish sanasi=2021-03-31|ish=pharmaphorum.com|til=en-GB}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
Kompaniya 1999-yilda Shvetsiyaning Astra AB va Britaniyaning Zeneca Group&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=20 July 2009 |title=Global 500 – Pharmaceuticals |work=Fortune |url=https://money.cnn.com/magazines/fortune/global500/2009/industries/21/index.html |url-status=live |access-date=19 August 2010 |archive-url=https://web.archive.org/web/20100823093009/https://money.cnn.com/magazines/fortune/global500/2009/industries/21/index.html |archive-date=23 August 2010}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Key facts|url=http://www.astrazeneca.com/about-us/key-facts/|arxivurl=https://web.archive.org/web/20100908083639/http://www.astrazeneca.com/about-us/key-facts/|arxivsana=8 September 2010|kirish sanasi=1 September 2010|nashriyot=AstraZeneca}}&amp;lt;/ref&amp;gt; qoʻshilishi natijasida tashkil etilgan (oʻzi 1993-yilda Imperial Chemical Industries farmatsevtika operatsiyalarining qoʻshilishi natijasida tashkil topgan). Birlashgandan beri u dunyodagi eng yirik farmatsevtika kompaniyalari qatoriga kirdi va koʻplab korporativ xaridlarni amalga oshirdi, jumladan Cambridge Antibody Technology (2006-yilda), MedImmune (2007-yilda), Spirogen (2013-yilda) va Definiens (2014-yilda MedImmune tomonidan). Uning [[Tadqiqot va texnologik ishlanmalar|tadqiqot va ishlanmalari]] uchta strategik markazda jamlangan: Kembrij, Angliya; [[Gyoteborg|Gothenburg]], Shvetsiya va [[Gaithersburg]], [[Maryland|Merilend]], AQSh&amp;lt;ref name=&amp;quot;Fierce2013reorg&amp;quot;&amp;gt;{{Yangiliklar manbasi |last=Carroll |first=John |date=18 March 2013 |title=UPDATED: AstraZeneca to ax 1,600, relocate thousands in global R&amp;amp;D reshuffle |work=fiercebiotech.com |publisher=FierceBiotech |url=http://www.fiercebiotech.com/node/124651}}&amp;lt;/ref&amp;gt;. AstraZeneca [[London fond birjasi|London fond birjasida]] asosiy listingga ega va [[FTSE 100 indeksi|FTSE 100 indeksining]] tarkibiy qismi hisoblanadi.&lt;br /&gt;
&lt;br /&gt;
== Tarixi ==&lt;br /&gt;
Astra AB 1913-yilda [[Shvetsiya|Shvetsiyaning]] Södertälje shahrida 400 nafar shifokor va aptekachilar tomonidan tashkil etilgan&amp;lt;ref&amp;gt;{{Kitob manbasi|url=http://pubs.acs.org/journals/pharmcent/index.html|title=The Pharmaceutical Century: Ten Decades of Drug Discovery|date=17 November 2000|publisher=ACS Publications|location=Washington, D.C.|chapter=Organizational Portraits – AstraZeneca|accessdate=14 July 2008|chapterurl=http://pubs.acs.org/journals/pharmcent/company3.html}}&amp;lt;/ref&amp;gt;. 1993-yilda Britaniya kimyoviy kompaniyasi ICI (toʻrtta Britaniya kimyo kompaniyasidan tashkil topgan) oʻzining [[Dori|farmatsevtika]] korxonalarini, agrokimyoviy va ixtisoslashtirilgan korxonalarini ajratib, Zeneca Group PLC ni tashkil qildi&amp;lt;ref name=&amp;quot;history&amp;quot;&amp;gt;{{Veb manbasi|sarlavha=Our History - AstraZeneca Careers|url=http://www.astrazenecacareers.com/content/aboutAZ/ourCompany/ourHistory/astrazeneca-our-history-corporate-evolution.asp|ish=AstraZeneca Careers}}&amp;lt;/ref&amp;gt;. Nihoyat, 1999-yilda Astra va Zeneca Group bosh qarorgohi Londonda joylashgan AstraZeneca plc.ni tashkil qilish uchun birlashdi&amp;lt;ref name=&amp;quot;history&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://www.thefreelibrary.com/AstraZeneca+Selects+Wilmington,+Del.+for+New+US+Headquarters.-a054504139|sarlavha=AstraZeneca Selects Wilmington, Del. for New US Headquarters|qaralgan sana=2022-12-07|arxivsana=2018-10-01|arxivurl=https://web.archive.org/web/20181001220452/https://www.thefreelibrary.com/AstraZeneca+Selects+Wilmington,+Del.+for+New+US+Headquarters.-a054504139}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== 2000-06 ===&lt;br /&gt;
2002-yilda uning Iressa (gefitinib) preparati Yaponiyada kichik hujayrali boʻlmagan oʻpka saratoni uchun monoterapiya sifatida tasdiqlangan&amp;lt;ref&amp;gt;{{Veb manbasi|sana=23 September 2002|sarlavha=AstraZeneca&amp;#039;s Iressa FDA committee judgement expected tomorrow|url=http://www.iii.co.uk/investment/detail?type=news&amp;amp;code=cotn%3AAZN.L&amp;amp;it=&amp;amp;articleid=4474187&amp;amp;action=article|kirish sanasi=7 July 2013}}&amp;lt;/ref&amp;gt;. 2004-yil 3-yanvarda AstraZeneca kompaniyasining sobiq direktori doktor Robert Nolan ZI Medical boshqaruv jamoasini tuzdi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=ZI is dripping with promise|url=http://www.highbeam.com/doc/1G1-111836523.html|arxivurl=https://web.archive.org/web/20140611131904/http://www.highbeam.com/doc/1G1-111836523.html|arxivsana=2014-06-11}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2005-yilda kompaniya Buyuk Britaniyaning KuDOS Pharmaceuticals biotexnologik kompaniyasini 120 million funt sterlingga sotib oldi&amp;lt;ref&amp;gt;[https://www.telegraph.co.uk/finance/2928954/AstraZeneca-buys-biotech-company-for-120m.html AstraZeneca buys biotech company for £120m] &amp;#039;&amp;#039;The Telegraph&amp;#039;&amp;#039;, 23 December 2005&amp;lt;/ref&amp;gt; va Astex bilan saratonga qarshi hamkorlik shartnomasini tuzdi&amp;lt;ref&amp;gt;[http://www.elsevierbi.com/deals/200520449 AstraZeneca and Astex ally for anticancer agents] Business Intelligence, 1 July 2005&amp;lt;/ref&amp;gt;. Shuningdek, u [[Pennsilvaniya|Pennsylvania]] Bio tijorat tashkilotining Diamond aʼzosi boʻlganligini eʼlon qildi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Pennsylvania Bio – Member Listings|url=http://www.pennsylvaniabio.org/membership/listings.asp|arxivurl=https://web.archive.org/web/20051214215037/http://www.pennsylvaniabio.org/membership/listings.asp|arxivsana=14 December 2005|kirish sanasi=8 October 2005|ish=Pennsylvania Bio web site}}&amp;lt;/ref&amp;gt;. 2006-yilda, 2004-yilda boshlangan hamkorlik aloqalaridan soʻng, AstraZeneca 702 million funt sterlingga Cambridge Antibody Technology kompaniyasini sotib oldi&amp;lt;ref&amp;gt;[http://news.bbc.co.uk/1/hi/business/4771615.stm AstraZeneca to buy CAT for £702m] BBC News, 15 May 2006&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== 2007-12 yillar ===&lt;br /&gt;
2007-yil fevral oyida AstraZeneca 150 AQSh dollariga virusga qarshi terapiyani kashf etish va rivojlantirishga qaratilgan Arrow Therapeutics kompaniyasini million sotib olishga rozi boʻldi&amp;lt;ref&amp;gt;[https://web.archive.org/20120708051536/http://articles.marketwatch.com/2007-02-01/news/30828561_1_astrazeneca-anglo-swedish-therapies AstraZeneca agrees to buy Arrow Therapeutics for US$150M] Marketwatch, 1 February 2007&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |title=AstraZeneca to pay 305.2B to purchase rival MedImmune; Deal sees London-based drugmaker take on debt for the first time in order to fill product line |work=Bloomberg |url=https://www.bloomberg.com/}}&amp;lt;/ref&amp;gt; AstraZeneca keyinchalik oʻzining barcha biologik operatsiyalarini MedImmune deb nomlangan maxsus biologik boʻlimga birlashtirdi&amp;lt;ref name=&amp;quot;astrazeneca.com&amp;quot;&amp;gt;[https://www.nytimes.com/2007/04/24/business/24drug-web.html AstraZeneca Buys MedImmune for US$ 15.6 Billion] &amp;#039;&amp;#039;The New York Times&amp;#039;&amp;#039;, 24 April 2007&amp;lt;/ref&amp;gt;. 2010-yilda AstraZeneca 2004-yilda Sanofi-Aventis yuqumli kasalliklarga qarshi boʻlinmasining qoʻshma korxonasi sifatida tashkil etilgan antibiotiklarni kashf qiluvchi Novexel Corp kompaniyasini sotib oldi. Astra ushbu xarid orqali NXL-104 (CEF104) (CAZ-AVI) eksperimental antibiotikini sotib oldi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=23 December 2009|sarlavha=AstraZeneca To Acquire Infection Research Company Novexel And Expand Collaboration With Forest Laboratories|url=http://www.astrazeneca.com/Media/Press-releases/Article/20091223--AstraZeneca-To-Acquire-Infection-Research-Company-Nov|kirish sanasi=20 February 2015}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Novexel to be Acquired by AstraZeneca|url=http://www.prnewswire.com/news-releases/novexel-to-be-acquired-by-astrazeneca-79982037.html|kirish sanasi=20 February 2015}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2011-yilda AstraZeneca Xitoyning generiklar biznesi boʻlgan Guangdong BeiKang farmatsevtika kompaniyasini sotib oldi &amp;lt;ref&amp;gt;[http://www.pmlive.com/pharma_news/astrazeneca_acquisition_generics_firm_china_Guangdong_BeiKang_352964 AstraZeneca to buy Chinese generics firm] {{Webarxiv|url=https://web.archive.org/web/20200308150841/http://www.pmlive.com/pharma_news/astrazeneca_to_buy_chinese_generics_firm_352964 |date=2020-03-08 }} Healthcare News, 8 December 2011&amp;lt;/ref&amp;gt;. 2012-yil fevral oyida AstraZeneca va Amgen yalligʻlanish kasalliklarini davolash boʻyicha hamkorlikni eʼlon qildi&amp;lt;ref&amp;gt;[http://www.medcitynews.com/2012/04/astra-zeneca-and-amgen-collaborate-on-treatments-for-inflammatory-diseases/ AstraZeneca and Amgen collaborate on treatments for inflammatory diseases] Medcity News, 4 February 2012&amp;lt;/ref&amp;gt;. Keyin 2012-yil aprel oyida AstraZeneca boshqa biotexnologiya kompaniyasi Ardea Biosciencesni 1,26 milliard dollarga sotib oldi&amp;lt;ref&amp;gt;[https://dealbook.nytimes.com/2012/04/23/astrazeneca-to-buy-ardea-for-1-26-billion/ AstraZeneca Reaches $1.26 Billion Deal for Ardea Biosciences] &amp;#039;&amp;#039;The New York Times&amp;#039;&amp;#039;, 23 April 2012&amp;lt;/ref&amp;gt;. 2012-yil iyun oyida AstraZeneca va [[Bristol Myers Squibb]] Amylin Pharmaceuticals biotexnologiya kompaniyasini birgalikda sotib olish boʻyicha ikki bosqichli bitimni eʼlon qildi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Peacock |first=Louisa |date=30 June 2012 |title=AstraZeneca to pay £2.2bn towards &amp;#039;joint venture&amp;#039; diabetes deal |work=The Daily Telegraph |location=London |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9366647/AstraZeneca-to-pay-2.2bn-towards-joint-venture-diabetes-deal.html |url-status=dead |access-date=1 July 2012 |archive-url=https://web.archive.org/web/20120804165139/http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9366647/AstraZeneca-to-pay-2.2bn-towards-joint-venture-diabetes-deal.html |archive-date=4 August 2012}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;reut30612&amp;quot;&amp;gt;{{Yangiliklar manbasi |date=30 June 2012 |title=Bristol-Myers to buy Amylin for about US$5.3 billion |work=Reuters |url=https://www.reuters.com/article/us-amylin-bristolmyerssquibb-idUSBRE85T01O20120630 |access-date=1 July 2012}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2013-yil ====&lt;br /&gt;
2013-yil mart oyida AstraZeneca yirik korporativ qayta qurish rejalarini eʼlon qildi, shu jumladan, Buyuk Britaniyaning Cheshirdagi Alderley Park va Loughboro va Shvetsiyadagi Lunddagi tadqiqot va ishlanmalarini yopish, 500 dollar sarmoya{{Nbsp}}kiritishni boshladi&amp;lt;ref name=&amp;quot;Fierce2013reorg&amp;quot;/&amp;gt;. AstraZeneca shuningdek, 2016-yilda korporativ shtab-kvartirasini Londondan Kembrijga koʻchirishini eʼlon qildi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=18 March 2013 |title=AstraZeneca to axe 1,600 jobs in overhaul of drug R&amp;amp;D |work=Reuters |url=http://uk.reuters.com/article/uk-astrazeneca-rd-idUKBRE92H0I320130318 |access-date=24 May 2014 |archive-date=2020-03-08 |archive-url=https://web.archive.org/web/20200308192614/https://uk.reuters.com/article/uk-astrazeneca-rd-idUKBRE92H0I320130318 |url-status=dead }}&amp;lt;/ref&amp;gt; Ushbu eʼlon 1600 ta ish joyini qisqartirish haqidagi eʼlonni oʻz ichiga olgan; uch kundan keyin u qoʻshimcha 2300 ish oʻrinlarini qisqartirishini eʼlon qildi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=21 March 2013 |title=AstraZeneca to cut 2,300 more jobs |work=USA Today |url=https://www.usatoday.com/story/money/business/2013/03/21/astrazeneca-cuts/2005357/ |access-date=24 May 2014}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |title=AstraZeneca increase job cuts to 5,050 |publisher=HR Grapevine |url=http://www.hrgrapevine.com/markets/hr/article/2013-03-21-astrazeneca-increase-cuts-to-5-050 |access-date=29 October 2014}}&amp;lt;/ref&amp;gt;. Shuningdek, u uchta terapevtik yoʻnalishga eʼtibor qaratishini eʼlon qildi: nafas olish tizimining yalligʻlanishi va autoimmuniteti, yurak-qon tomir va metabolik kasalliklar va onkologiya&amp;lt;ref&amp;gt;AstraZeneca Press Release. 21 March 2013 [http://www.astrazeneca.com/Media/Press-releases/Article/20130321--astrazeneca-outlines-strategy-return-to-growth-scientific-leadership AstraZeneca outlines strategy to return to growth and achieve scientific leadership]&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2014-yil ====&lt;br /&gt;
2014-yil 19-mayda AstraZeneca [[Pfizer]] kompaniyasining har bir aksiya uchun 55 funt sterlinglik „yakuniy taklifini“ rad etdi, bu esa kompaniyani 69,4 funt sterlingga baholadi. Agar sotib olish davom etsa, Pfizer dunyodagi eng yirik dori ishlab chiqaruvchisiga aylangan boʻlardi. Bitim, shuningdek, Britaniya kompaniyasining eng yirik xorijiy sotib olinishi boʻlar edi. Britaniyada ko‘pchilik, jumladan siyosatchilar va olimlar ham kelishuvga qarshi chiqqan edi&amp;lt;ref name=&amp;quot;PfizerBid&amp;quot;&amp;gt;{{Yangiliklar manbasi |title=AstraZeneca rejects Pfizer &amp;#039;final&amp;#039; takeover offer, triggers major drop in shares |publisher=London Mercury |url=http://www.londonmercury.com/index.php/sid/222128733/scat/0f440bf3fff89f01/ht/AstraZeneca-rejects-Pfizer-final-takeover-offer-triggers-major-drop-in-shares |url-status=dead |access-date=20 May 2014 |archive-url=https://web.archive.org/web/20140520215930/http://www.londonmercury.com/index.php/sid/222128733/scat/0f440bf3fff89f01/ht/AstraZeneca-rejects-Pfizer-final-takeover-offer-triggers-major-drop-in-shares |archive-date=20 May 2014}}&amp;lt;/ref&amp;gt;. 2014-yil avgust oyida kompaniya Mitsubishi Tanabe Pharma bilan diabetik nefropatiya boʻyicha uch yillik hamkorlikka kirishganini eʼlon qildi&amp;lt;ref name=&amp;quot;AstraZenecaMTPC&amp;quot;&amp;gt;{{Yangiliklar manbasi |date=20 August 2014 |title=AstraZeneca and MTPC come together for research on diabetic nephropathy drugs |publisher=Business Sun |url=http://www.genengnews.com/gen-news-highlights/astrazeneca-mtpc-partner-to-validate-diabetic-nephropathy-targets/81250258/?kwrd=Medicines%20Company |access-date=21 August 2014}}&amp;lt;/ref&amp;gt;. 2014-yil sentabr oyida kompaniya Eli Lilli bilan [[Alzheimer kasalligi|Altsgeymer kasalligini]] davolashda foydalaniladigan BACE inhibitori — AZD3292 nomzodini ishlab chiqish va tijoratlashtirishda kuchlarni birlashtirdi. Bitim kompaniyaga 500 million dollargacha foyda keltirishi mumkin&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=GEN - News Highlights:Lilly Joins AstraZeneca to Co-Develop BACE Inhibitor for Alzheimer&amp;#039;s|url=http://www.genengnews.com/gen-news-highlights/lilly-joins-astrazeneca-to-co-develop-bace-inhibitor-for-alzheimer-s/81250353/|ish=GEN}}&amp;lt;/ref&amp;gt;. Kompaniya, shuningdek, Pharmacyclics va Janssen Biotech bilan birgalikda davolash usullarini oʻrganish boʻyicha I/II-bosqich sinov hamkorligini boshladi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=4 November 2014|sarlavha=GEN - News Highlights:AstraZeneca Bolsters Oncology Focus with Definiens Purchase, Trial Collaboration|url=http://www.genengnews.com/gen-news-highlights/astrazeneca-bolsters-oncology-focus-with-definiens-purchase-trial-collaboration/81250554/|ish=GEN}}&amp;lt;/ref&amp;gt;. Shuningdek, oʻsha yilning noyabr oyida kompaniya oʻzining lipodistrofiyani davolash biznesini Aegerion Pharmaceuticals kompaniyasiga 325 million AQSh dollaridan ortiqroqqa sotishga rozi boʻldi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=6 November 2014|sarlavha=GEN - News Highlights:Aegerion Snaps Up Rare Disease Drug from AstraZeneca for US$325M+|url=http://www.genengnews.com/gen-news-highlights/aegerion-snaps-up-rare-disease-drug-from-astrazeneca-for-325m/81250562/?kwrd=astrazeneca|ish=GEN}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2015-yil ====&lt;br /&gt;
Fevral oyida kompaniya 600 million AQSh dollari miqdorida Actavis brendi ostidagi respirator dori biznesiga AQSh va Kanada huquqlarini sotib olishini eʼlon qildi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=5 February 2015|sarlavha=GEN - News Highlights:AstraZeneca Buys U.S., Canadian Rights to Actavis Respiratory Drugs for $600M+|url=http://www.genengnews.com/gen-news-highlights/astrazeneca-buys-u-s-canadian-rights-to-actavis-respiratory-drugs-for-600m/81250897/|ish=GEN}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2017-yil ====&lt;br /&gt;
&lt;br /&gt;
2017-yil sentabr oyida kompaniya rahbari Leif Yoxansson, agar Brexit qiyin bo‘lsa, tadqiqot va ishlab chiqarish faoliyatini Buyuk Britaniyadan uzoqlashtirish bo‘yicha „birinchi qadamlar“ni qo‘yishni rejalashtirgan edi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=28 September 2017|sarlavha=AstraZeneca has started preparations for hard Brexit, including operations move from UK|url=https://www.thelocal.se/20170928/astrazeneca-has-started-preparing-for-hard-brexit-including-operations-move-from-uk|kirish sanasi=29 September 2017|ish=The Local}}&amp;lt;/ref&amp;gt;. 2017-yilda u sotish boʻyicha dunyodagi oʻn birinchi yirik dori kompaniyasi boʻldi va ilmiy-tadqiqot investitsiyalari boʻyicha yettinchi oʻrinni egalladi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Christel |first=Michael |date=28 June 2017 |title=Pharm Exec&amp;#039;s Top 50 Companies 2017 |work=Pharmaceutical Executive, Volume 37, Issue 6 |publisher=Pharm Exec |url=http://www.pharmexec.com/pharm-execs-top-50-companies-2017 |access-date=14 September 2017 |archive-date=2017-09-14 |archive-url=https://web.archive.org/web/20170914215729/http://www.pharmexec.com/pharm-execs-top-50-companies-2017 |url-status=dead }}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2018-yil ====&lt;br /&gt;
2018-yil fevral oyida AstraZeneca oltita dastlabki bosqichdagi eksperimental dori vositalarini Viela Bio nomi bilan tanilgan yangi biotexnologiya kompaniyasiga aylantirayotganini eʼlon qildi, uning qiymati 250 million AQSh dollari&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Hirschler |first=Ben |date=28 February 2018 |title=AstraZeneca spins off autoimmune drugs into new biotech company |work=Reuters |url=https://www.reuters.com/article/us-astrazeneca-biotech/astrazeneca-spins-off-autoimmune-drugs-into-new-biotech-company-idUSKCN1GC0OL |access-date=4 March 2018}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2019-yil ====&lt;br /&gt;
2019-yil mart oyida AstraZeneca Daiichi Sankyo Co Ltd bilan ko‘krak bezi saratonini eksperimental davolashda ishlash uchun 6,9 milliard AQSh dollari miqdorida pul to‘lashini eʼlon qildi. AstraZeneca 3,5 milliard dollarlik aksiyalar chiqarilishidan tushgan mablag‘ning bir qismini bitimni moliyalashtirish uchun ishlatishni rejalashtirmoqda.&lt;br /&gt;
&lt;br /&gt;
==== 2020-yil ====&lt;br /&gt;
2020-yil fevral oyida AstraZeneca oʻzining global huquqlarini (Yevropa, Kanada va Isroildan tashqari) Movantik preparatiga, Redhill Biopharmaga sublitsenziya berishga rozi boʻldi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=AstraZeneca divests global rights to Movantik|url=https://www.worldpharmanews.com/astrazeneca/5147-astrazeneca-divests-global-rights-to-movantik|kirish sanasi=2020-02-28|ish=worldpharmanews.com}}&amp;lt;/ref&amp;gt;. 2020-yil 27-dekabr kuni AstraZeneca bosh direktori Paskal Soriot [[Oxford universiteti|Oksford universitetining]] COVID-19 vaksinasi bilan „yutuq formulasini aniqlaganliklarini“ aytdi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=27 December 2020|sarlavha=Oxford vaccine researchers have found &amp;#039;winning formula&amp;#039;, AstraZeneca chief says|url=https://www.independent.co.uk/news/uk/home-news/oxford-vaccine-coronavirus-variant-b1779212.html|kirish sanasi=27 December 2020|ish=The Independent}}&amp;lt;/ref&amp;gt;. 2020-yil 30-dekabrda Buyuk Britaniya [[Oxford–AstraZeneca COVID-19 vaksinasi|Oksford-AstraZeneca COVID-19 vaksinasidan]] favqulodda foydalanishni tasdiqladi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Is good news for India on the vaccine front here?|url=https://www.timesnownews.com/health/article/is-good-news-for-india-on-the-vaccine-front-here/700965|kirish sanasi=2020-12-31|ish=www.timesnownews.com|til=en}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|sana=30 December 2020|sarlavha=Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK|url=https://www.bbc.co.uk/news/health-55280671|kirish sanasi=30 December 2020|ish=BBC News|nashriyot=BBC}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Das |first=Ruchika Chitravanshi &amp;amp; Sohini |date=2020-12-31 |title=India&amp;#039;s Covid vaccine hope rolls over to 2021; panel to meet again on Jan 1 |work=Business Standard India |url=https://www.business-standard.com/article/current-affairs/india-s-covid-vaccine-hope-rolls-over-to-2021-panel-to-meet-again-on-jan-1-120123100045_1.html |access-date=2020-12-31}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
==== 2021-yil ====&lt;br /&gt;
2021-yil iyul oyida AstraZeneca Alexion Pharmaceuticals kompaniyasini sotib oldi&amp;lt;ref name=&amp;quot;auto&amp;quot;&amp;gt;{{Yangiliklar manbasi |last=Higgins-Dunn |first=Noah |date=July 21, 2021 |title=AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases |work=[[FiercePharma]] |url=https://www.fiercepharma.com/pharma/astrazeneca-closes-mega-39b-alexion-buyout-despite-antitrust-fears-making-a-splash-rare}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Cite press release |title=Acquisition of Alexion completed |date=July 21, 2021 |publisher=AstraZeneca |url=https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html}}&amp;lt;/ref&amp;gt;. 2021-yil oktabr oyida kompaniya Alexion orqali Caelum Biosciences va uni engil zanjirli (AL) [[amiloidoz]] uchun monoklonal davolashni (CAEL-101) 500 million dollargacha sotib oldi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Shabong |first=Yadarisa |last2=Ravikumar |first2=Sachin |date=29 September 2021 |title=AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-buys-drugmaker-caelum-deal-worth-up-500-mln-2021-09-29/ |via=www.reuters.com}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=AstraZeneca Buys Caelum BioSciences in $500 Million Deal|url=https://www.biospace.com/article/astrazeneca-exercises-option-to-buy-caelum-biosciences-in-500-million-deal/|ish=BioSpace}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==== 2022-yil ====&lt;br /&gt;
Iyul oyida kompaniya TeneoTwoʻni 1,3 milliard dollarga sotib olishini eʼlon qildi va bu qon saratoniga qarshi dori taklifini koʻpaytirdi&amp;lt;ref&amp;gt;{{Veb manbasi|url=https://www.reuters.com/markets/deals/astrazeneca-buy-oncology-firm-teneotwo-up-127-bln-2022-07-05/|sarlavha=AstraZeneca to buy biotech firm TeneoTwo for up to 59.27 billion|sana=5 July 2022}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Vaxzevria, AstraZeneca kompaniyasining COVID-19 pandemiyasiga qarshi javobi ==&lt;br /&gt;
[[Fayl:Oxford_AstraZeneca_COVID-19_vaccine_(2021)_I_(cropped).jpg|link=//upload.wikimedia.org/wikipedia/commons/thumb/7/70/Oxford_AstraZeneca_COVID-19_vaccine_%282021%29_I_%28cropped%29.jpg/220px-Oxford_AstraZeneca_COVID-19_vaccine_%282021%29_I_%28cropped%29.jpg|thumb| Oksford-AstraZeneca COVID-19 vaksinasi]]&lt;br /&gt;
2020-yil mart oyida kompaniya turli xalqaro sogʻliqni saqlash tashkilotlarini [[Individual himoya vositalari|COVID]] [[COVID-19 pandemiyasi|-19 pandemiyasini]] yumshatishda qoʻllab-quvvatlash uchun shaxsiy himoya vositalarini, shu jumladan 9 million yuz niqoblarini xayriya qilishini eʼlon qildi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=30 March 2020|sarlavha=Coronavirus: AstraZeneca donates nine million face masks and steps up Covid-19 drugs research|url=https://www.cambridgeindependent.co.uk/business/coronavirus-astrazeneca-donates-nine-million-face-masks-and-steps-up-covid-19-drugs-research-9104685/|kirish sanasi=28 April 2020|ish=Cambridge Independent}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2020-yil 23-noyabrda Oksford-AstraZeneca vaksina muvaffaqiyatli sinovdan o‘tkazilganini eʼlon qildi va bu odamlarning 70 foizida simptomlar rivojlanishining oldini oldi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=2021-12-30|sarlavha=Why AstraZeneca Covid-19 vaccine approval &amp;#039;good news for whole world&amp;#039;? UK minister answers|url=https://www.hindustantimes.com/world-news/why-astrazeneca-covid-19-vaccine-approval-good-news-for-whole-world-uk-minister-answers/story-FgbnyjvsXNx76SbfF5UpYK.html|kirish sanasi=2020-12-31|ish=Hindustan Times|til=en}}&amp;lt;/ref&amp;gt;. Tadqiqotchilar, agar ular dozani oʻzgartirsalar, bu koʻrsatkich 90% ga yetishi mumkin deb oʻylashdi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Gallagher |first=James |date=2020-11-23 |title=Covid-19: Oxford University vaccine is highly effective |language=en-GB |work=BBC News |url=https://www.bbc.com/news/health-55040635 |access-date=2020-11-24}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2021-yil yanvar oyida Hindiston Oksford-AstraZeneca vaktsinasidan foydalanishni maʼqulladi va bu dunyoning ikkinchi aholisi boʻlgan mamlakatida ommaviy emlash kampaniyasiga yoʻl ochdi. Oksford-AstraZeneca oʻqini COVISHIELD brendi bilan Hindiston Serum Instituti (SII) tomonidan mahalliy ishlab chiqarilishi eʼlon qilindi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=2021-01-02|sarlavha=India approves AstraZeneca&amp;#039;s COVID-19 vaccine|url=https://in.reuters.com/article/health-coronavirus-india-vaccine/india-approves-astrazenecas-covid-19-vaccine-idINKBN29707F|kirish sanasi=2021-01-02|ish=Reuters|til=en|qaralgan sana=2022-12-07|arxivsana=2021-01-02|arxivurl=https://web.archive.org/web/20210102120417/https://in.reuters.com/article/health-coronavirus-india-vaccine/india-approves-astrazenecas-covid-19-vaccine-idINKBN29707F}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
2021-yil 29-yanvarda Yevropa dori vositalari agentligi (EMA) 18 yoshdan oshgan odamlarga AZD1222 uchun shartli marketing ruxsatnomasini berishni tavsiya qildi&amp;lt;ref&amp;gt;{{Veb manbasi|sana=29 January 2021|sarlavha=EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU Share|url=https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu}}&amp;lt;/ref&amp;gt;. 2021-yil mart oyi o‘rtalariga kelib, [[Niderlandiya]], Daniya, Norvegiya, Islandiya, [[Bolgariya]] va Irlandiya trombotsitlar sonining kamayishi bilan qon quyqalarining „kamdan-kam uchraydigan kombinatsiyasi“ning oltita holatidan xavotir tufayli AstraZeneca vaksinasini qo‘llashni to‘xtatib qo‘yishdi. Vaqtinchalik toʻxtash Yevropa Ittifoqining dori vositalarini tartibga soluvchi organining tavsiyasiga qarshi boʻlib, u vaksinaning foydalari har qanday xavflardan ustun ekanligini aytdi&amp;lt;ref&amp;gt;{{Veb manbasi|muallif=Nectar Gan|sana=2021-03-15|sarlavha=European countries suspend AstraZeneca vaccinations despite advice from EU medicines regulator|url=https://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-03-15-21/h_278fceebf74385b79c6e5bbe470253d6|kirish sanasi=2021-03-15|ish=CNN|til=en}}&amp;lt;/ref&amp;gt;.Doston kamroq ol&lt;br /&gt;
&lt;br /&gt;
== Operatsiyalar ==&lt;br /&gt;
[[Fayl:Astrahassleentrance.JPG|link=//upload.wikimedia.org/wikipedia/commons/thumb/f/f0/Astrahassleentrance. JPG/220px-Astrahassleentrance. JPG|right|thumb| [[Shvetsiya]], [[Gyoteborg|Gothenburg]] shahridagi AstraZeneca R&amp;amp;D obyekti]]&lt;br /&gt;
[[Fayl:AstraZeneca_HQ_in_Cambridge_UK_under_construction_in_sunset.jpg|link=//upload.wikimedia.org/wikipedia/commons/thumb/2/2a/AstraZeneca_HQ_in_Cambridge_UK_under_construction_in_sunset.jpg/220px-AstraZeneca_HQ_in_Cambridge_UK_under_construction_in_sunset.jpg|right|thumb| Angliyaning [[Cambridge|Kembrij]] shahrida yangi AstraZeneca korporativ bosh qarorgohi qurilmoqda]]&lt;br /&gt;
AstraZeneca [[onkologiya]], yurak-qon tomir, oshqozon-[[Gastroenterologiya|ichak]], [[infeksiya]], nevrologiya, [[Pulmonologiya|nafas olish]] va [[yalligʻlanish]] sohalaridagi kasalliklarni davolash uchun farmatsevtika va biotexnologiya mahsulotlarini ishlab chiqadi, ishlab chiqaradi va sotadi&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=AstraZeneca|url=https://www.europeanpharmaceuticalreview.com/organisations/astrazeneca/|kirish sanasi=24 February 2021|nashriyot=European Pharmaceutical Review}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
AstraZeneca kompaniyasining korporativ bosh qarorgohi Buyuk Britaniyaning Kembrij shahrida joylashgan va asosiy [[Tadqiqot va texnologik ishlanmalar|tadqiqot va ishlanmalar]] (R&amp;amp;D) markazlari [[Cambridge|Kembrij]] (Buyuk Britaniya), [[Gaithersburg]] (Merilend, AQSh), [[Gyoteborg|Gothenburg]] (Shvetsiya) va [[Varshava]] (Polsha) shaharlarida joylashgan&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Nowe inwestycje w B+R w Polsce po spotkaniu Premiera Morawieckiego z Prezesem AstraZeneca podczas Światowego Forum Ekonomicznego w Davos|url=https://www.astrazeneca.pl/aktualnosci/Nowe_inwestycje_w_BR_w_Polsce.html|arxivurl=https://web.archive.org/web/20200213023049/https://www.astrazeneca.pl/aktualnosci/Nowe_inwestycje_w_BR_w_Polsce.html|arxivsana=13 February 2020|kirish sanasi=2020-02-13|ish=astrazeneca.pl|til=en}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
== Manbalar ==&lt;br /&gt;
{{manbalar}}&lt;/div&gt;</description>
			<pubDate>Mon, 10 Aug 2026 14:24:04 GMT</pubDate>
			<dc:creator>Programmer</dc:creator>
			<comments>https://ziyosfera.uz/ziyo/Munozara:AstraZeneca_plc</comments>
		</item>
</channel></rss>